Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors

Clinical Cancer Research

Volumn 6, Issue 5, 2000, Pages 2094-2103

  Pavco, Pamela A ^a   Bouhana, Karyn S ^a   Gallegos, Anna M ^a   Agrawal, Arun ^a   Blanchard, Karin S ^a   Grimm, Susan L ^a   Jensen, Kristi L ^a   Andrews, Lori E ^a   Wincott, Francine E ^a   Pitot, Patrice A ^b   Tressler, Robert J ^b,c   Cushman, Cynthia ^b,d   Reynolds, Mark A ^a,e   Parry, Tom J ^a,f  

^a Sirna Therapeutics Inc   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Matrix Pharmaceutical Inc   (United States)

^d Elan Pharmaceuticals   (United Kingdom)

^e Incyte Microarrays ^*  (United States)

^f GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; RIBOZYME; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; GENE EXPRESSION; GENE FUNCTION; METASTASIS; METASTASIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RNA CLEAVAGE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, LEWIS LUNG; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RNA, CATALYTIC; RNA, MESSENGER; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0034069028     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 285: 1182-1186, 1971.
2. Thomas, K. A. Vascular endothelial growth factor, a potent and selective angiogenic agent. J. Biol. Chem., 271: 603-606, 1996.
3. Martiny-Baron, G., and Marmé, D. VEGF-mediated tumour angiogenesis: a new target for cancer therapy. Curr. Opin. Biotechnol., 6: 675-680, 1995.
4. Myoken, Y., Kayada, Y., Okamoto, T., Kan, M., Sato, G. H., and Sato, J. D. Vascular endothelial cell growth factor (VEGF) produced by A-431 human epidermoid carcinoma cells and identification of VEGF membrane binding sites. Proc. Natl. Acad. Sci. USA, 88: 5819-5823, 1991.
5. Plate, K., Breier, G., Weich, H., and Risau, W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature (Lond.), 359: 845-848, 1992.
6. Plate, K. H., Breier, G., Millauer, B., Ullrich, A., and Risau, W. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res., 53: 5822-5827, 1993.
7. Brown, L. F., Berse, B., Jackman, R. W., Tognazzi, K., Guidi, A. J., Dvorak, H. F., Senger, D. R., Connolly, J. L., and Schnitt, S. J. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum. Pathol., 26: 86-91, 1995.
8. Warren, R., Yuan, H., Matli, M., Gillett, N., and Ferrara, N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Investig., 95: 1789-1797, 1995.
9. Mattern, J., Koomagi, R., and Volm, M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br. J. Cancer, 73: 931-934, 1996.
10. Nicol, D., Hii, S-I., Walsh, M., Teh, B., Thompson, L., Kennett, C., and Gotley, D. Vascular endothelial growth factor expression is increased in renal cell carcinoma. J. Urol., 157: 1482-1486, 1997.
11. Hlatky, L., Tsionou, C., Hahnfeldt, P., and Coleman, C. N. Mammary fibroblasts may influence breast tumor angiogenesis via hypoxia-induced vascular endothelial growth factor up-regulation and protein expression. Cancer Res., 54: 6083-6086, 1994.
12. Shweiki, D., Itin, A., Soffer, D., and Keshet, E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (Lond.), 359: 843-845, 1992.
13. Takahashi, A., Sasaki, H., Kim, S., Tobisu, K-I., Kakizoe, T., Tsukamoto, T., Kumamoto, Y., Sugimura, T., and Terada, M. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res., 54: 4233-4237, 1994.
14. Samoto, K., Ikezaki, K., Ono, M., Shono, T., Kohno, K., Kuwano, M., and Fukui, M. Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res., 55: 1189-1193, 1995.
15. Pötgens, A. J. G., Lubsen, N. H., van Altena, M. C., Schoenmakers, J. G. G., Ruiter, D. J., and de Waal, R. M. Vascular permeability factor expression influences tumor angiogenesis in human melanoma lines xenografted to nude mice. Am. J. Pathol., 146: 197-209, 1995.
16. Zhang, H. T., Craft, P., Scott, P. A., Ziche, M., Weich, H. A., Harris, A. L., and Bicknell, R. Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J. Natl. Cancer Inst., 87: 213-219, 1995.
17. Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., and Ferrara, N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (Lond.), 362: 841-844, 1993.
18. Melnyk, O., Shuman, M., and Kim, K. Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth. Cancer Res., 56: 921-924, 1996.
19. Shibuya, M. Role of VEGF-flt receptor system in normal and tumor angiogenesis. Adv. Cancer Res., 67: 281-316, 1995.
20. Strawn, L., McMahon, G., App, H., Schreck, R., Kuchler, W., Longhi, M., Hui, T., Tang, C., Levitzki, A., Gazit, A., Chen, I., Keri, G., Orfi, L., Risau, W., Flamme, I., Ullrich, A., Hirth, P., and Shawyer, L. Flk-1 as a target for tumor growth inhibition. Cancer Res., 56: 3540-3545, 1996.
21. Barleon, B., Siemeister, G., Martiny-Baron, G., Weindel, K., Herzog, C., and Marmé, D. Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase 1 (FLT-1) and a soluble variant of FLT-1 in human vascular endothelial cells. Cancer Res., 57: 5421-5425, 1997.
22. Jakeman, L. B., Winer, J., Bennett, G. L., Altar, C. A., and Ferrara, N. Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J. Clin. Investig., 89: 244-253, 1992.
23. Ferrara, N., Heinsohn, H., Walder, C. E., Bunting, S., and Thomas, G. R. The regulation of blood vessel growth by vascular endothelial growth factor. Ann. N. Y. Acad. Sci., 752: 246-255, 1995.
24. Millauer, B., Wizigmann-Voos, S., Schnürch, H., Martinez, R., Moller, N. P., Risau, W., and Ullrich, A. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell, 72: 835-846, 1993.
25. Waltenberger, J., Claesson-Welsh, L., Siegbahn, A., Shibuya, M., and Heldin, C. H. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J. Biol. Chem., 269: 26988-26995, 1994.
26. Barleon, B., Totzke, F., Herzog, C., Blanke, S., Kremmer, E., Siemeister, G., Marmé, D., and Martiny-Baron, G. Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1. J. Biol. Chem., 272: 10382-10388, 1997.
27. Fong, G. H., Rossant, J., Gertsenstein, M., and Breitman, M. L. Role of the Fit-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature (Lond.), 376: 66-70, 1995.
28. Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X. F., Breitman, M. L., and Schuh, A. C. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature (Lond.), 576: 62-66, 1995.
29. Shalaby, F., Ho, J., Stanford, W. L., Fischer, K. D., Schuh, A. C., Schwartz, L., Bernstein, A., and Rossant, J. A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis. Cell, 89: 981-990, 1997.
30. Usman, N., and Stinchcomb, D. T. Design, synthesis, and function of therapeutic hammerhead ribozymes. In: R. Eckstein and D. M. J. Lilley (eds.), Nucleic Acids and Molecular Biology, Vol. 10, pp. 243-264. Berlin: Springer-Verlag, 1996.
31. Beigelman, L., McSwiggen, J., Draper, K., Gonzalez, C., Jensen, K., Karpeisky, A., Modak, A., Matulic-Adamic, J., DiRenzo, A., Haeberli, P., Sweedler, D., Tracz, D., Grimm, S., Wincott, F., Thackray, V., and Usman, N. Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance. J. Biol. Chem., 270: 25702-25708, 1995.
32. Flory, C. M., Pavco, P. A., Jarvis, T. C., Lesch, M. E., Wincott, F. E., Beigelman, L., Hunt, S. W., III, and Schrier, D. J. Nuclease-resistant ribozymes decrease stromelysin mRNA levels in rabbit synovium following exogenous delivery to the knee joint. Proc. Natl. Acad. Sci. USA, 93: 754-758, 1996.
33. Parry, T. J., Cushman, C., Gallegos, A. M., Agrawal, A. B., Richardson, M., Andrews, L. E., Maloney, L., Mokler, V. R., Wincott, F. E., and Pavco, P. A. Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA. Nucleic Acids Res., 27: 2569-2577, 1999.
34. Sioud, M., and Sørensen, D. R. A nuclease-resistant protein kinase C α ribozyme blocks glioma cell growth. Nat. Biotechnol., 16: 556-561, 1998.
35. O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., Lane, W. S., Cao, Y., Sage, E. H., and Folkman, J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79: 315-328, 1994.
36. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1: 27-31, 1995.
37. Wincott, F., DiRenzo, A., Shaffer, C., Grimm, S., Tracz, D., Workman, C., Sweedler, D., Gonzalez, C., Scaringe, S., and Usman, N. Synthesis, deprotection, analysis and purification of RNA and ribozymes. Nucleic Acids Res., 23: 2677-2684, 1995.
38. Burgin, A. B., Gonzalez, C., Matulic-Adamic, J., Karpeisky, A. M., Usman, N., McSwiggen, J. A., and Beigelman, L. Chemically modified hammerhead ribozymes with improved catalytic rates. Biochemistry, 35: 14090-14097, 1996.
39. Clark, J. D., Baldwin, R. L., Bayne, K. A., Brown, M. J., Gebhart, G. F., Gonder, J. C., Gwathmey, J. K., Keeling, M. E., Kohn, D. F., Robb, J. W., Smith, O. A., Steggerda, J-A. D., Vandenbergh, J. G., White, W. J., Williams-Blangero, S., and VandeBerg, J. L. Guide for the Care and Use of Laboratory Animals. Washington DC: National Academy Press, 1996.
40. ™) in the mouse. Antisense & Nucleic Acid Drug Development, 9: 271-277, 1999.
41. Keyt, B. A., Nguyen, H. V., Berleau, L. T., Duarte, C. M., Park, J., Chen, H., and Ferrara, N. Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis. J. Biol. Chem., 271: 5638-5646, 1996.
42. Yuan, F., Chen, Y., Dellian, M., Safabakhsh, N., Ferrara, N., and Jain, R. K. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an antivascular endothelial growth factor/vascular permeability factor antibody. Proc. Natl. Acad. Sci. USA, 93: 14765-14770, 1996.
43. Millauer, B., Shawver, L. K., Plate, K. H., Risau, W., and Ullrich, A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature (Lond.), 367: 576-579, 1994.
44. Shibuya, M., Seetharam, L., Ishii, Y., Sawano, A., Gotoh, N., Matsushime, H., and Yamaguchi, S. Possible involvement of VEGF-FLT tyrosine kinase receptor system in normal and tumor angiogenesis. Proceedings of the International Symposium Princess Takahatsu Cancer Research Fund, 24: 162-170, 1994.